GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AgeX Therapeutics Inc (AMEX:AGE) » Definitions » Operating Margin %

AgeX Therapeutics (AgeX Therapeutics) Operating Margin % : -4,650.65% (As of Dec. 2023)


View and export this data going back to 2018. Start your Free Trial

What is AgeX Therapeutics Operating Margin %?

Operating Margin % is calculated as Operating Income divided by its Revenue. AgeX Therapeutics's Operating Income for the three months ended in Dec. 2023 was $-3.58 Mil. AgeX Therapeutics's Revenue for the three months ended in Dec. 2023 was $0.08 Mil. Therefore, AgeX Therapeutics's Operating Margin % for the quarter that ended in Dec. 2023 was -4,650.65%.

Warning Sign:

AgeX Therapeutics Inc operating margin has been in a 5-year decline. The average rate of decline per year is -85%.

The historical rank and industry rank for AgeX Therapeutics's Operating Margin % or its related term are showing as below:

AGE' s Operating Margin % Range Over the Past 10 Years
Min: -20514.71   Med: -2797.78   Max: -599.5
Current: -7014.09


AGE's Operating Margin % is ranked worse than
89.47% of 1026 companies
in the Biotechnology industry
Industry Median: -175.525 vs AGE: -7014.09

AgeX Therapeutics's 5-Year Average Operating Margin % Growth Rate was -85.00% per year.

AgeX Therapeutics's Operating Income for the three months ended in Dec. 2023 was $-3.58 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Dec. 2023 was $-9.96 Mil.

Warning Sign:

AgeX Therapeutics Inc has never been profitable in the past 3 years. It lost money every year.


AgeX Therapeutics Operating Margin % Historical Data

The historical data trend for AgeX Therapeutics's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AgeX Therapeutics Operating Margin % Chart

AgeX Therapeutics Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Operating Margin %
Get a 7-Day Free Trial -726.79 -2,797.78 -5,582.64 -20,514.71 -7,014.08

AgeX Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Operating Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -22,275.00 -21,580.00 -20,955.56 -5,076.09 -4,650.65

Competitive Comparison of AgeX Therapeutics's Operating Margin %

For the Biotechnology subindustry, AgeX Therapeutics's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AgeX Therapeutics's Operating Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, AgeX Therapeutics's Operating Margin % distribution charts can be found below:

* The bar in red indicates where AgeX Therapeutics's Operating Margin % falls into.



AgeX Therapeutics Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

AgeX Therapeutics's Operating Margin % for the fiscal year that ended in Dec. 2023 is calculated as

Operating Margin %=Operating Income (A: Dec. 2023 ) / Revenue (A: Dec. 2023 )
=-9.96 / 0.142
=-7,014.08 %

AgeX Therapeutics's Operating Margin % for the quarter that ended in Dec. 2023 is calculated as

Operating Margin %=Operating Income (Q: Dec. 2023 ) / Revenue (Q: Dec. 2023 )
=-3.581 / 0.077
=-4,650.65 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


AgeX Therapeutics  (AMEX:AGE) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


AgeX Therapeutics Operating Margin % Related Terms

Thank you for viewing the detailed overview of AgeX Therapeutics's Operating Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


AgeX Therapeutics (AgeX Therapeutics) Business Description

Traded in Other Exchanges
Address
1101 Marina Village Parkway, Suite 201, Alameda, CA, USA, 94501
AgeX Therapeutics Inc is a biotechnology company engaged in the development and commercialization of novel therapeutics targeting human aging. The firm through its PureStem and induced Tissue Regeneration (iTR) technologies develops medicines designed to address some of the unsolved problems in aging. Its PureStem-derived cell-based therapeutic candidates in development are AGEX-VASC1, AGEX-BAT1 and AGEX-iTR1547.
Executives
Jean-christophe Renondin director 505 PARK AVENUE 14TH FLOOR, NEW YORK NY 10022
Juvenescence Us Corp. director, 10 percent owner 303A COLLEGE ROAD EAST, PRINCETON NJ 08540
Joanne M. Hackett director C/O AGEX THERAPEUTICS, INC.,, 1101 MARINA VILLAGE PARKWAY, SUITE 201, ALAMEDA CA 94708
Park Andrea Eun Jae officer: Chief Financial Officer C/O AGEX THERAPEUTICS, INC., 965 ATLANTIC AVE., SUITE 101, ALAMEDA CA 94501
Michael H May director 965 ATLANTIC AVENUE, SUITE 101, ALAMEDA CA 94501
Michael D West director, officer: Chief Executive Officer AGEX THERAPEUTICS, INC., 1101 MARINA VILLAGE PARKWAY, SUITE 201, ALAMEDA CA 94501
Michael H. Mulroy director 1300 N. KELLOGG DRIVE, SUITE D, ANAHEIM CA 92807
Russell Skibsted officer: Chief Financial Officer 15 TRANQUILITY PLACE, LADERA RANCH CA 92694
Judith Segall officer: Corporate Secretary 1010 ATLANTIC AVENUE, SUITE 102, ALAMEDA CA 94501
Hal Sternberg officer: Vice President-Research 935 PARDEE STREET, BERKELEY CA 94710
Annalisa Jenkins director C/O ARDELYX, INC., 34715 ARDENWOOD BLVD, SUITE 100, FREMONT CA 94555
John F Mauldin director 3204 BEVERLY DRIVE, DALLAS TX 75205
Gregory Bailey director 4 A CHESHAM STREET, LONDON X0 SW1X8DT
Juvenescence Ltd 10 percent owner 1ST FLOOR, VIKING HOUSE, ST PAULS SQUARE, RAMSEY Y8 IM8 1GB
Nafees Naseer Malik officer: Chief Operating Officer C/O AGEX THERAPEUTICS, INC., 1010 ATLANTIC AVE, STE 102, ALAMEDA CA 94501